Clinical Trials Directory

Trials / Completed

CompletedNCT06561282

Predictive Role of Glucose/Potassium Ratio on Mortality in Major Burns.

The Predictive Role of Glucose/Potassium Ratio for Mortality in Patients With Major Burn Trauma

Status
Completed
Phase
Study type
Observational
Enrollment
200 (actual)
Sponsor
Konya Meram State Hospital · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

The aim of this observational study is to investigate the role of the glucose-potassium ratio in predicting mortality in patients with major burn trauma. The main question it aims to answer is: Can the glucose-potassium ratio predict mortality in major burn patients? The glucose-to-potassium ratios of major burn patients at the time of initial hospitalization will be determined, and their relationship with mortality will be analyzed.

Detailed description

Major burns, especially electrical burns, facial burns, inhalation burns, burns with large burn surface areas, and deep burns, have a high mortality risk. Early detection of this risk may be critical to reducing mortality rates. For this reason, trauma centers are working on rapid and effective prognostic markers. In trauma and stress situations, glucose levels rise while potassium levels fall due to increased catecholamines. The literature reports that hyperglycemia, also known as the glucose-potassium ratio, can rapidly and effectively predict morbidity and mortality in patients suffering from subarachnoid hemorrhage, pulmonary embolism, traumatic brain injury, or blunt abdominal trauma. Many publications show that increased glucose is associated with mortality and morbidity in critical illnesses and trauma. The isolated glucose-potassium ratio has a higher predictive ability for mortality and morbidity compared to glucose and potassium levels. In this study, investigators aimed to examine the prognostic value of the glucose-to-potassium ratio in participants with major burn trauma.

Conditions

Timeline

Start date
2022-05-01
Primary completion
2024-05-01
Completion
2024-07-01
First posted
2024-08-20
Last updated
2024-08-21

Locations

1 site across 1 country: Turkey (Türkiye)

Source: ClinicalTrials.gov record NCT06561282. Inclusion in this directory is not an endorsement.